Navigation Links
Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call
Date:11/7/2008

HOPKINTON, Mass., Nov. 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that they will host a conference call on Friday, November 14th, 2008 at 9:00am ET to review the third quarter ending September 30, 2008 and discuss other matters related to the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

To access the conference call, please dial 877-718-5095 for domestic and 719-325-4818 for international calls. The code for this conference call is 3501954. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the conference call and will be available through Friday, November 28, 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative t
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
10. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2009)...zerland, Nov. 10 ,, ... Q4 2009 Q4 2008 % Change FY 2...-- ------- -------- ------- ------- --------, ...$17,237 $20,199 (15)%, Income (Loss) from,... $264 (22)% ($1,833) $1,095 -, Di...
(Date:11/10/2009)... At a time when health is a major concern for man...uncertain, Easy Pha-max, an internationally recogn...tates. Consumers now have more options to consider...t better time to have options than now. Easy Pha-m...al products that can address many health concerns ...
(Date:11/10/2009)... It is now possible to achieve exceptionally smoo... of hard materials such as ceramics, carbide and h...he new Diamond Flex-Hone® honing tool from B... Los Angeles (PRWEB) November 10, 2009 -- Using ...ed to the ends of flexible filaments, the Diamond ...
(Date:11/9/2009)... Businesses of all sizes looking to fast-track pr...mic have a new resource at their disposal. , ...9, 2009 -- Human resource (HR) professionals looki... for the H1N1 pandemic have a new resource at thei...nter for Infectious Disease Research and Policy (C...
(Date:11/9/2009)...a, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Mindray M...ng developer, manufacturer and,marketer of medical...naudited,financial results for the third quarter a...ighlights for Operations as of September 30, 2009,... million, an increase of, 3.1% over the thir...
Breaking Medicine News(10 mins):Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 2Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 3Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 4Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 5Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 6Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 7Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 8Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 9Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 10Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 11Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 12Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 13Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 14Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 15Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 16Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 17Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 18Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 19Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 20Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 21Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 22Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 23Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 24Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 25Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 26Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 27Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 28Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 29Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 30Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 31Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 32Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 33Health News:Major Biotechnology Franchise Company Expands Rapidly Throughout the USA Amidst Mounting Health Concerns 2Health News:Diamond Honing Tool Technology: The New Standard in Surface Finishing of Hard Materials 2Health News:New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 2
...stitute (NHLBI) of the National Institutes of Heal...ng North American clinical trial of diabetes and c...y concerns after review of available data, althoug... to intensively lower blood glucose (sugar) below ...
... mark,its 10th anniversary of delivering identity ...industry, Sentillion, the company that created hea...r-end results. In Q4, Sentillion,added 10 new cust...ity and access management products for single,sign...
...t Increase in Sales from Same ... Greenway Medical Technologies,Inc., a leading pr...R),practice management and interoperability functi...me period in fiscal 2007,and 83 percent from the s...
...out suspected cancer-causing agents, such as deodo...sessment tool has been developed through the Cance...rra Health (SESIH) by a University of New South Wa...y such as using deodorants, artificial sweeteners ...
...es, constructed with soft lithography, should boos...re brain-behavior connections and to screen new ph... infections in humans, report 10 scientists at thr...iled in a paper appearing online ahead of regular ...
...Inc., a global,supplier of infant formulas and nut...anies to accommodate its growing number of interna... into Asia, where it formed PBM,(Guangzhou) Nutrit...007,the magazine,s annual ranking of America,s fas...
Other Medicine News:Health News:Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 2Health News:Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 3Health News:Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 4Health News:Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 5Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 2Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 3Health News:Greenway Medical Technologies Continues Record Setting Growth 2Health News:Greenway Medical Technologies Continues Record Setting Growth 3Health News:Greenway Medical Technologies Continues Record Setting Growth 4Health News:Reducing cancer panic 2Health News:New devices to boost nematode research on neurons and drugs 2Health News:New devices to boost nematode research on neurons and drugs 3
(Date:11/9/2009)...stCall/ -- Volcano Corporation (Nasdaq: VOLC ), a...of products for the diagnosis and treatment of cor...at it will be participating in the Third Annual Ca...mber 10. ,, The presentation by Scott Huenneken...in at 1 p.m., Pacific Standard Time (4 p.m., Easte...
(Date:11/9/2009)...a., Nov. 9 Hill-Rom (N...e formation of a joint venture that will focus on ... of surface replacement systems that are intended ...ements for surfaces that are technologically obsol... a global leader in patient support systems and re...
(Date:11/9/2009)...Asia-FirstCall/ -- American Oriental,Bioengineerin...a pharmaceutical,company dedicated to improving he...ercialization of a broad range of prescription and...d that it plans to release third quarter 2009,fina...the market closes. , The Company will hol...
Breaking Medicine Technology:Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 2Hill-Rom and Encompass Group Form Joint Venture 2Hill-Rom and Encompass Group Form Joint Venture 3Hill-Rom and Encompass Group Form Joint Venture 4Hill-Rom and Encompass Group Form Joint Venture 5New Drug Could Work Against Leukemia 50663 1Sexist jokes favor the mental mechanisms that justify violence against women 50661 1Sexist jokes favor the mental mechanisms that justify violence against women 50661 2Center receives grant renewal for hypertension and vascular disease studies 50659 1Center receives grant renewal for hypertension and vascular disease studies 50659 2
...t. 31 United,Therapeutics Corporation (Nasdaq: U...., announced today that they will release the resu... inhaled formulation of treprostinil,in pulmonary ...Thursday,November 1, 2007. United Therapeutics wi... on November 1, 2007, to a full hour to accommodat...
...stal Research,Associates, LLC announced today that...(R) (EIO(R)) on CEL-SCI Corporation (Amex: CVM )....ww.crystalra.com . CEL-SCI Corporation develops i...s. Its primary product candidate is Multikine(R), ...t targets treatment-naive,newly diagnosed head and...
Other Medicine Technology:Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 3
Access Vitamin B12
Quantaphase II B12/RIA
Autoimmunity Screening Panel 1
...ies that have decided to change to the ELISA metho...A ANAs correlation with IFA and many user friendly...n. While no ELISA ANA currently on the market is c...A screen has been shown to be quite effective at d...
Medicine Products: